

NeoGenomics, Inc.

Chris Smith, Chief Executive Officer

JP Morgan Healthcare Conference
January 8, 2024

Safe Harbor Statements

This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to business, operations, and financial conditions of the Company. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "suggest", "project", "forecast", "estimate," "intend," "plan," "would," "should" and "could," and similar expressions or words, identify forward-looking statements. Although the Company believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Actual results could differ materially from those projected in the Company's forward-looking statements due to numerous known and unknown risks and uncertainties. All forward-looking statements speak only as of the date of this presentation and are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to revise or update this presentation to reflect events or circumstances after the date hereof.

Information contained in this presentation concerning our industry and the markets in which we operate, including our general expectations and market position, market opportunity and market size, is based on information from various sources, on assumptions that we have made that are based on such information and other similar sources and on our knowledge of, and expectations about, the markets for our service offerings. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

This presentation contains financial measures, such as adjusted EBITDA, adjusted gross margin and adjusted net income, which are considered non-GAAP financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). Adjusted EBITDA, adjusted gross margin and adjusted net income, unusual or other items that we do not consider indicative of our ongoing operating performance. The Company's definitions of these non-GAAP measures may differ from similarly titled measures used by others. The Company generally uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company's historical operating results, comparison to competitors' operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company's business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management strongly encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables in this presentation. We cannot estimate or project these items and they may have a substantial and unpredictable impact on our results presented in accordance with GAAP.



Mission

We save lives by improving patient care.

Vision

We are becoming the world's leading cancer testing, information, and decision support company by providing uncompromising quality, exceptional service, and innovative solutions.



A dense, repeating grid of small, square portraits of people from various ethnicities, ages, and genders, all smiling or looking positively. The portraits are in shades of blue and white, creating a textured, mosaic-like background.


Cancer prevalence is on the rise.

1 in 2 men
will develop cancer
in their lifetime

1 in 3 women
will develop cancer
in their lifetime

The Cancer Testing Market

Providing significant growth opportunity



Market Drivers

1. Cancer incidence and prevalence on the rise
2. Treatment paradigm shifting towards earlier stage care
3. Increased access, complexity and testing
4. NGS/Therapy Selection is growing at ~15-20% annually with a long runway

We Have a Unique Position

In the Cancer Diagnostics Market



Pure Play Oncology Diagnostic Lab

Driving Sustainable & Profitable Growth

- Mid-teens profitability
- High single-digit revenue growth
- 600+ test menu
- Driving innovation through R&D



TEMPUS

We are an industry leader in oncology diagnostics

We have a comprehensive oncology menu offering of over 600 tests

We focus on developing innovative oncology diagnostic solutions

We have a significant share of oncology patient testing volume in the US

We have a broad network of labs to enable superior service and rapid TAT

We have two distinct Clinical sales teams with deep oncology expertise & strong customer relationships

We generate over 100M Clinical data points annually


We have over 2,200 teammates between the US and UK

Right Test, Right Patient, Right Time

Delivering world class care through personalized medicine for the community oncologist




Anatomic
Pathology




Flow
Cytometry



Cytogenetics




FISH



Molecular



MRD



NEO Production Labs
With Modular Automation



NEO Networked
Analysis Lab



HQ & NEO Production Lab –
Validating Automation



Profitably Grow Our Core Business



Increase Volume in Base
Business, and NGS

Expand and optimize commercial
organization...Win in Oncology

Continue to improve Revenue
Cycle Management

Accelerate Advanced Diagnostics



Launch New Innovative Products

- Neo Comprehensive 2.0 (NGS)
- Liquid Biopsy CGP

Continue to develop Clinical
Evidence and reimbursement
pathways for MRD

Improve Pharma Margins

Drive Value Creation




Drive Operating Efficiencies
and Improve Gross Margin

LIMS Implementation

Enhance automation and digital
implementation

FDA Readiness



% of Revenue

Clinical Service Division

Trusted partner for pathology and community oncology




Portfolio

- Tailored portfolio solutions to specifically address customer's testing needs
- Market leader in heme testing with ~25% of Heme NGS market volume
- More than 50 NGS tests in our menu which represents approximately 25% of the clinical revenue and is growing in excess of 35% through Q3-'23



Commercial Execution

- 100-person+ sales team strategically deployed to address the most relevant opportunities
- Digital tools and capabilities to enhance commercial effectiveness
- Exceptional relationships with oncologists and pathologists
- Over 200 managed care contracts supporting patients




Scalable Business Support

- Enhanced regulatory capabilities and readiness
- Reimbursement and revenue cycle sophistication to accelerate AUP
- Customer integration and interfaces for bi-direction communication with customers
- Wrap around services to support patients and their treatment decisions



Operational Excellence

- Maintain rapid turnaround time to support consumer needs, test to treatment
- Optimized lab footprint across testing network improving regional access and redundancy
- Automation driving cost per test efficiencies



% of Revenue

Advanced Diagnostics Division

Custom assay development and validation expertise across all technologies



R&D

- Building strong clinical evidence for MRD and therapy selection
- Launching next generation NGS products
 - Therapy selection CGP
 - Liquid biopsy CGP
 - Next generation MRD technology and applications



Pharma Services

- Large selection in Oncology offerings spanning simple amino assays to MRD technology
- Support across all stages of Pharma drug development
- Experienced QA/RA support
- Day 1 readiness program to new Oncology drug approvals targeting the community-based setting



Informatics

- Generating 100M+ Clinical data points for Pharma each year to accelerate commercialization of precision medicine
- Large database of robust de-identified data
- AI-enabled data capture, allowing for partnerships to develop algorithms
- Collaborations to investigate real-world clinical outcomes in Heme malignancies



ADx Technology


- Largest DNA/RNA myeloid profile on the market
- Full disease state offerings for both solid tumor and heme cancers in therapy selection
- MRD solid tumor applications
- Lung targeted liquid biopsy tests for therapy selection

Changing the Treatment Paradigm with MRD

The power of a personalized tumor informed assay with high sensitivity and specificity

MRD detects recurrence sooner than Imaging

RaDaR's high sensitivity allows for earlier identification of residual disease when comparing to current SOC and opens the possibility of interventions prior to overt metastatic disease



- 28 additional studies in progress to support clinical efficacy for RaDaR
- RaDaR assay validated in Breast, Lung, Colorectal and H&N
- Medicare approval for breast cancer Medicare patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.*
- Additional Medicare submission for expanded breast indications, Lung and Head & Neck indications

1. Cutts R, et al. AACR 2021 Abstract 536 2. Lipsyc-Sharf M, et al. J Clin Oncol. 2022;40:2408-2419.
3. Gale D, et al. Ann Oncol. 2022;33(5):500-510. 4. Flach S, et al. Br J Cancer. 2022;136:1186-1195.

* The coverage includes patients with a personal history of high-risk stage I/II/III HR+/HER2- breast cancer, five or more years from diagnosis who presently do not have evidence of disease.

Financial Performance YTD Through 3Q'23

- Total YoY Revenue Increased 18%
 - Clinical Revenue Increased 18%
 - ADx Revenue Increased 17%
- Adjusted EBITDA improved by \$41M or 88%
- NGS revenue grew over 35%
- Cash Flow from operations improved by \$43M or 68% vs PY

REVENUE UP

18%

TO \$436M

ADJ. GROSS PROFIT

\$192M

MARGIN: 43.9%

10TH

CONSECUTIVE INCREASE VS
PRIOR YEAR IN REVENUE PER
TEST

ADJ. EBITDA UP

88%

Current FY '23 Expectations

- Continued Focus on Long-term, Sustainable Revenue Growth
- Adjusted EBITDA Growth Exceeds Revenue Growth Due to Improving Gross Profit and Operating Leverage
- Continued Investments Salesforce and Operational Efficiencies and Lab Automation
- Expect to Be Adjusted EBITDA Positive in Q4 of 2023

15% – 16%
Revenue Growth

FY: \$585 – \$592 Million

Up from \$565 - \$575 Million


92% – 98% Adjusted
EBITDA Growth

FY: (\$4) to (\$1) Million

Up from (\$13) – (\$10) Million

Momentum Continues

Total Quarterly Revenues



(\$ in millions)

Quarterly Adj. EBITDA



(\$ in millions)

Key Takeaways

- Significant addressable market across cancer care continuum
- Market leading position with over 600 tests having differentiated modalities focused on community oncologists and pathologists
- Strong volume and revenue growth in 2023, turning Adj. EBITDA positive with momentum carrying into 2024
- Well positioned to win; building long-term sustainable growth



Serving patients.



Saving lives.™

© 2024 NeoGenomics Laboratories, Inc. All rights reserved.
All other trademarks are the property of their respective owners.